While AI startups burn millions chasing vague use cases, Mrimath secured FDA clearance for a life-saving device with just $200K in funding. This isn't a hype story; it's a masterclass in capital efficiency in the most regulated industry on earth.

"Mrimath isn't just selling software; they are selling time—the most precious commodity when battling Glioblastoma."

The traffic data paints a picture of a company focused on B2B sales cycles rather than consumer marketing. With only 80 monthly visits but a high direct traffic percentage (42%), they aren't relying on SEO to close deals. They are likely closing enterprise contracts through direct outreach and medical conferences—a classic MedTech go-to-market strategy.

• Capital Efficiency:** $3.5M revenue on $200K funding is elite performance.
• Regulatory Moat:** FDA clearance creates a massive barrier to entry for competitors.
• Niche Domination:** Focusing solely on GBM segmentation allows for deeper, more accurate AI models.